Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128386 | 0.78 | — | — | |
| SCHEMBL8751985 | 0.77 | ALDH1A1 (0.40) | BTKMAPK8ADORA2AADORA1ELANE | |
| SCHEMBL12889421 | 0.76 | NUDT1 (0.41) | BTKMAPK8ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL2879587 | 0.75 | L3MBTL1 (0.51) | ELANENUDT1HTTTTBK1TTBK2 | |
| SCHEMBL17979568 | 0.74 | KCNA3 (0.42) | SMN1; SMN2MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2933088 | 0.74 | — | — | |
| SCHEMBL15111394 | 0.73 | SMPD1 (0.41) | ADORA1NPC1RAB9A | |
| SCHEMBL2893270 | 0.73 | MEN1 (0.40) | LMNAMAPTHTTALDH1A1NPC1 | |
| SCHEMBL2940699 | 0.72 | PDE3B (0.36) | ADORA2AADORA1ELANELMNAMAPT | |
| SCHEMBL8589835 | 0.71 | DYRK1A (0.31) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2348029-A1 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives | Pharmasset, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | MCCARTHY JAMES R (US) | 2003-06-12 | — | — | US | disclosed |
| US-6017923-A | Carbo-acyclic nucleoside derivatives as antiviral and antineoplastic agents | HOECHST MARION ROUSSEL, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| US-5977325-A | NUCLEOSIDE DERIVATIVES USEFUL AS ANTICARCINOGENIC/ANTITUMOR AGENTS AND VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0705264-B1 | CARBO-ACYCLIC NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | MERRELL PHARMA INC (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5792841-A | ANTIVIRAL, ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5616702-A | ANTITUMOR AGENTS, VIRICIDES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5607925-A | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0705264-A1 | CARBO-ACYCLIC NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000515-A1 | CARBO-ACYCLIC NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5378693-A | Antitumor agents or viricides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0372268-B1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMA (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0372268-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| US-3947444-A | Process for producing N1 -(Dihydroxyalkyl)-5-substituted uracils | GILLER SOLOMON ARONOVICH | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063659-A1 | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT14, NUDT1 | BTK 4298/4885MAPK8 3988/4885ADORA2A 130/4885 |
| US-20030109484-A1 | Novel 2'-halomethylidene, 2'-ethenylidene and 2'ethynyl cytidine, uridine and guanosine derivatives | UMPS, NUDT1, NUDT14 | BTK 4346/4885MAPK8 4102/4885ADORA2A 135/4885 |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | BTK 1393/4885MAPK8 1602/4885ADORA2A 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.